These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3707811)

  • 21. Evaluation of oxprenolol and metoprolol Oros systems in the dog: comparison of in vivo and in vitro drug release, and of drug absorption from duodenal and colonic infusion sites.
    Fara JW; Myrback RE; Swanson DR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):91S-95S. PubMed ID: 4005134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension.
    Resnekov EB; Havard CW
    Eur J Clin Pharmacol; 1978 Nov; 14(2):77-81. PubMed ID: 363434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of oxprenolol in normal subjects.
    Mason WD; Winer N
    Clin Pharmacol Ther; 1976 Oct; 20(4):401-12. PubMed ID: 10124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
    Leahey WJ; Neill JD; Varma MP; Shanks RG
    Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zero-order release formulation of oxprenolol hydrochloride with swelling and erosion control.
    Devi KP; Rao KV; Baveja S; Fathi M; Roth M
    Pharm Res; 1989 Apr; 6(4):313-7. PubMed ID: 2748519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.
    Davis SS; Washington N; Parr GD; Short AH; John VA; Lloyd P; Walker SM
    Br J Clin Pharmacol; 1988 Oct; 26(4):435-43. PubMed ID: 3056482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience with a slow-release formulation of oxprenolol.
    Waal-Manning HJ; Spears GF
    N Z Med J; 1978 Apr; 87(609):245-6. PubMed ID: 275650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative bioavailability of oral sustained-release and regular-release oxprenolol tablets at steady-state.
    Gupta PK; Lim JK; Zoest AR; Lam FC; Hung CT
    Biopharm Drug Dispos; 1991 Oct; 12(7):493-503. PubMed ID: 1932612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative bioavailability of different oral sustained release oxprenolol tablets.
    Leucuta SE; Follidis M; Capalneanu R; Mocan A
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):178-84. PubMed ID: 9725478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of oxprenolol in the elderly.
    Kendall MJ
    Am J Cardiol; 1983 Nov; 52(9):54D-56D. PubMed ID: 6637853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once daily dosage beta-blockade: antihypertensive efficacy of slow release oxprenolol as related to renin and age.
    Bühler FR; Lütold BE; Küng M; Koller FJ
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):37-43. PubMed ID: 1071402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxprenolol placental transfer, plasma concentrations in newborns and passage into breast milk.
    Sioufi A; Hillion D; Lumbroso P; Wainer R; Olivier-Martin M; Schoeller JP; Colussi D; Leroux F; Mangoni P
    Br J Clin Pharmacol; 1984 Sep; 18(3):453-6. PubMed ID: 6487485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report.
    John VA; Shotton PA; Moppert J; Theobald W
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):203S-206S. PubMed ID: 4005123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Slow-Trasicor (sustained-release oxprenolol hydrochloride 160 mg) in the treatment of essential hypertension: a multicentre evaluation of 4,400 patients.
    Forrest WA
    Br J Clin Pract; 1977 Nov; 31(11):181-6. PubMed ID: 339937
    [No Abstract]   [Full Text] [Related]  

  • 36. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.
    Theeuwes F; Swanson DR; Guittard G; Ayer A; Khanna S
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):69S-76S. PubMed ID: 4005132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics and dynamics of oxprenolol: a simulation study with six subjects.
    Saunders L; Ingram D; Warrington SJ
    J Pharm Pharmacol; 1985 Nov; 37(11):802-6. PubMed ID: 2867161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial.
    Materson BJ; Friedman BA; Hla KM; Neidorf BS; Gray JM; Glazer N; Gross S
    Drug Intell Clin Pharm; 1983 Jan; 17(1):51-4. PubMed ID: 6337801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of oxprenolol in spontaneously hypertensive rats as determined by an enzyme immunoassay.
    Kawashima K
    J Pharmacobiodyn; 1981 Jul; 4(7):534-40. PubMed ID: 7028945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.